AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01458509 — intervention group
Intervention type: BEHAVIORAL
Intervention: Surveys
Description: Web: Study participants will be sent an email containing a link to the web survey. The participants will click on the link and complete the survey. Study participants may also login to the web survey independent of the link received via email. In each group, administration of a survey including the BFI, PRO-CTCAE sexual function items, and QOL LASA and in each group, the survey will be conducted once a month over a six-month period. This group will not receive a phone call.
Study NCT03284619 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imager linear accelerator
Description: The MR linear accelerator (MRL) integrates a radiotherapy accelerator and a diagnostic quality 1.5T MRI, enabling soft-tissue visualization during the actual radiation delivery for improved targeting. This enables on-line treatment optimization for precise radiation delivery. Better visualization of the tumour targets and the surrounding healthy tissues, at the exact moment of treatment, makes it possible to adapt the dose to the actual anatomy while optimally sparing normal tissues.
Study NCT03064295 — intervention group
Intervention type: DEVICE
Intervention: Myocardial Perfusion Cardiac MRI.
Description: MRI with administration of a contrast drug and a stress agent, if no contraindications are present. The gadolinium based contrast agent to be used in this study is either Gadavist (up to 0.2 mL/kg body weight (0.2 mmol/kg) or MultiHance (0.2 mmol/kg) The IV stress agent is regadenoson (0.4mg/5ml bolus) or adenosine (dosage based on subject's weight and is set at 140mcg/kg/min
Study NCT03064295 — intervention group
Intervention type: DRUG
Intervention: Contrast
Description: The intravenous gadolinium based contrast agent to be used in this study is either Gadavist (up to 0.2 mL/kg body weight (0.2 mmol/kg) or MultiHance (0.2 mmol/kg)
Study NCT03064295 — intervention group
Intervention type: DRUG
Intervention: Pharmacologic Stress Agent
Description: The stress agent administered intravenously is regadenoson (0.4mg/5ml bolus) or adenosine (dosage based on subject's weight and is set at 140mcg/kg/min
Study NCT04060173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABP-671
Description: ABP-671 is an investigational drug
Study NCT04060173 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT01687413 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy (IMRT)
Study NCT02554955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Participants will receive mycophenolate mofetil orally (one dose of 1.5 mg within 12 hours pretransplant, 1.5 mg BID within first week and 1 g/day BID from second week onwards) for 6 months.
Study NCT02554955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silrolimus
Description: Participants will receive sirolimus orally (3 mg/day) for 6 months.
Study NCT03534492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Infusion
Study NCT03534492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: P.O.
Study NCT01687413 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-modulated radiation therapy (IMRT)
Study NCT01687413 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Study NCT02582580 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Perineal massage
Description: Perineal massage should be practiced once a day, from the 34th week of gestation until the beginning of labor. It should obey the following sequence: the pregnant woman must be positioned comfortably and use intimate water based lubricant at her fingertips; start the massage in the outdoor area of the vulva with circular movements of the skin and connective tissue around the vagina and at the central tendon of the perineum, clockwise, clitoris to clitoris; introduce two thumb fingers or index and middle fingers into the vagina at a distance of approximately 4 centimeters; perform internal massaging with laterally semicircles towards the anus for 20 to 30 seconds; put pressure down towards the anus and to each side of the vagina until feeling a slight burning or stretching sensation and hold the position for 2 minutes; massage the lower half of the vaginal introitus in a movement simulating the letter U. All movements should be repeated four times.
Study NCT02582580 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Dilator
Description: Vaginal dilator Epi-No® should be used once a day for 15 minutes, from the 34th week of pregnancy until the beginning of labor. It should be coated with a condom and intimate water based lubricant and then be inserted into the vaginal canal in such way that the balloon stays two centimeters away from the vaginal introitus. The device will be inflated by manual pumping until the tolerable woman's limit. The pregnant woman will be encouraged to daily inflate a greater volume of compressed air into the balloon so that the amount of air is greater than the quantity in the previous day, achieving, day after day, a greater stretching of perivaginal structures, always respecting the individual tolerance limit. The amount of manual pumping imposed to inflate the balloon should be written in an Intervention Diary so that the next use, the pregnant woman will be sure that pumped the device more times than in the previous session.
Study NCT02582580 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscles training
Description: Pregnant women allocated to this group will perform pelvic floor muscles training. The progression of the protocol of this study will occur gradually in view of the peculiarities that involve the pelvic floor in the gestational stage and the ultimate goal is the promotion of an intact perineum after vaginal delivery. The exercises will obey a sequence, according to the gestation week, considering the following factors/parameters: exercise position, number and sustaining period of slow and fast contractions, and relaxation time between contractions. All contractions should be during the expiratory phase of breathing associated with an isometric contraction of the abdominal muscles and at the end of each series of contractions, perform a one minute interval between sets and in that time perform the diaphragmatic breathing exercise to promote overall relaxation. This protocol should be practiced once a day, every day from the 34th week of gestation until the beginning of labor.
Study NCT02684019 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: added to propofol sedation
Study NCT02684019 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulphate
Description: added to propofol sedation
Study NCT01325831 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation(rTMS)
Description: 10-day course of 10 Hz rTMS on left dorsolateral prefrontal cortex of the subjects.
Study NCT03334019 — intervention group
Intervention type: OTHER
Intervention: blood test
Description: Data collected on general population, farmers and veterinarians though questionnaires and blood samples.
Study NCT03569618 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tablet-based Game
Description: Tablet-based game aimed at improving processing speed and attention.
Study NCT03569618 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Tablet-based Game
Description: Tablet-based game aimed at improving processing speed and attention.
Study NCT01021865 — intervention group
Intervention type: DRUG
Intervention: Glucagon-Like-Peptide-1/Regadenoson/Perflutren Lipid Microsphere
Description: GLP-1 at a rate of 1.2 pmol/kg/min~Regadenoson as a stress agent 0.4mg IV given during MCE~Definity:0.6 ml of Definity diluted with 30ml of 0.9% saline infused by SYRINGE Infusion Pump
Study NCT02937792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intrathecal 15 mg bupivacaine
Description: spinal anesthesia with a large dose of bupivacaine 0.5% in elective caesarean section
Study NCT02575235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetylpyridinium Chloride (CPC)
Description: Two study groups take CPC of 1.5mg and 4.5mg daily for four weeks.
Study NCT02575235 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Control group takes the placebo for the same period.
Study NCT00432458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: 200 mg orally on days 1-28 of 28 day cycle
Study NCT00432458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: 4 mg\^2 by IV on day 1 every 84 days for 1 year and once per year thereafter
Study NCT01539655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vandetanib
Description: Oral tablets, 300 mg, single dose
Study NCT01325831 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham repetitive transcranial magnetic stimulation(rTMS)
Description: Sham repetitive transcranial magnetic stimulation(rTMS)
Study NCT00462098 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hyperbaric oxygen
Description: 40 sessions of 100% oxygen at 2 atmospheres of pressure for 2 hours each
Study NCT00462098 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: non-treated control group
Description: no change from routine care, no HBO
Study NCT02241044 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Argon plasma coagulation
Description: Argon plasma coagulation therapy was realized by an Olympus electrosurgical unit/APC unit (PSD-60/Endoplasma, Olympus Corporation, Tokyo, Japan), and its catheters were 2.3mm and 3.5 mm equipped with different endoscope channels.7 APC treatment used a coagulation mode at gas flow/power settings of 1.5L/min and 40 watt for duodenal ulcers and 40-60 watt for gastric ulcers.10 Operative distance between the probe and target bleeding ranged from 2 to 8 mm. Air warranted to be sucked frequently at endoscopy in an attempt at decrease of APC-induced smoke and gastric decompensation, with appropriate treatment of high-risk bleeding ulcers.
Study NCT02241044 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Distilled water
Description: Distilled water was then applied in aliquots of 0.5-2.0 mL, at and around the site of target bleeding, up to 25.0 ml if necessary. Injection amount was determined by endoscopists according to ulcer or vessel size and its location.
Study NCT02241044 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Distilled water
Description: Distilled water was then applied in aliquots of 0.5-2.0 mL, at and around the site of target bleeding, up to 25.0 ml if necessary. Injection amount was determined by endoscopists according to ulcer or vessel size and its location.
Study NCT04068064 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EABM training
Description: The training aims at associating gaming pictures with negative words and pictures of healthy activities with positive words. Gaming pictures are always presented with a pair of negative words. Pictures of healthy activities are always presented with a pair of positive words. Each picture is presented with a fixed pair of words. Participants will be instructed to select one word to get the most monetary reward. Specifically, in response to each gaming picture, selecting one word will have a 70% chance to get a monetary reward and the other word will have a 30% chance to get a monetary reward. A similar rationale applies to the pictures of healthy activities. The reward setting will help consolidate target associations.~Each training session includes 300 times/trials of each type of association, presented in pseudorandom way. The whole training includes 6 training sessions. Participants will receive one training session every days.
Study NCT04068064 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: sham training
Description: In the control group, neutral words instead of emotional words are used. All other settings are the same with those in the intervention group
Study NCT01539655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omeprazole
Description: Oral capsules, 40 mg, multiple doses
Study NCT01539655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranitidine
Description: Oral tables, 150 mg, multiple doses
Study NCT04619121 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIR-tPBM
Description: The treatment will last for 8 weeks and be bilateral and applied to the frontal areas with one application site on the left side and one on the right side (left and right forehead centered on the frontal eminences and per EEG sites on F3 and F4). Energy is administered with a radiation wavelength of 830 nm. The duration of irradiation is from 20 minutes at each application site (the 2 sites are irradiated at the same time which is equivalent to 20 minutes of total time) to 40 minutes at each site, up to 2 times per day. The treatment will follow these specifications: PBM (IR) irradiance of 33.2 mW/cm2, each treatment window area is 28.7 cm2; PBM (IR) fluence of up to 60 Joules/cm2; energy delivered per session per device up to 1.72 kJ for a total of up to 3.44 kJ.
Study NCT04619121 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham device
Description: The sham device is completely identical in appearance, but only emits neglectable energy to the brain.
Study NCT01107275 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rabies vaccine
Description: intradermal vaccination
Study NCT02850055 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physiotherapy
Description: 1. Leaflet care and health habits of the temporomandibular joint.~2. Program of cranio-cervical and temporomandibular exercises.~3. Massage of the cervical muscles and self care document for home.
Study NCT02850055 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific Manual Therapy
Description: 1. Leaflet care and health habits of the temporomandibular joint.~2. Program of cranio-cervical and temporomandibular exercises.~3. Massage of the cervical muscles and self care document for home.~4. Specific manual therapy techniques focusing on the temporomandibular joint and temporomandibular muscles.
Study NCT03753152 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: experimental
Description: Neuramis® Deep Lidocaine
Study NCT03753152 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comparator
Description: YVOIRE® Volume Plus
Study NCT00831233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The second and third doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections on Days 28 and 56, respectively.
Study NCT00831233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin
Description: Goserelin implants (3.6 mg) were inserted s.c. into the abdominal wall every 28 days. The second and third doses of goserelin were administered on Days 31 and 59, respectively.
Study NCT00831233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicalutamide
Description: On Day 0, three days before the first dose of goserelin on Day 3, patients began once-daily per-oral (p.o.) treatment with bicalutamide (50 mg) as anti-androgen flare protection; this treatment continued for 14 days after the first dose of goserelin.
Study NCT04417647 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VZ powder (purified clinoptilolite)
Description: VZ powder will be applied topically to the open surface of the verum treatment-assigned wound to cover the entire wound area. Following each VZ application, wounds will be protected by wound dressing (non-adhesive wound dressing (AdapticTM) and conventional protective Mepore® dressing).
Study NCT04417647 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard of care (SoC)
Description: wound cleansing (0.9% saline solution) and wound dressing (non-adhesive wound dressing (AdapticTM) and conventional protective Mepore® dressing) will be applied to the SoC-assigned wound.
Study NCT03417830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2315698 (CPHPC)
Description: GSK2315698 will be administered as 20 milligrams per hour (20 mg/hour) IV infusion (in the vein) for up to 72 hours followed by 60 milligrams (mg) three times daily as SC injection for 8 days. Dose level and frequency will be adjusted according to renal function.
Study NCT03417830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2398852 (unlabeled anti-SAP mAb)
Description: Subjects will be administered up to 490 mg of GSK2398852, IV. Dose level will be adjusted based on emerging imaging data.
Study NCT03417830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-GSK2398852 (89Zr-labeled anti-SAP mAb)
Description: 89Zr-GSK2398852 will be available as solution containing 10 mg 89Zr-GSK2398852 for Infusion. Subjects will be administered 37 (Megabecquerel) MBq radioactive dose of 89Zr-GSK2398852 by the IV route at each dosing session.
Study NCT02246088 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MT + NE
Description: Manual therapy will be applied using mobilization with movement (MWM) techniques. MWM will consist of a sustained manual glide of the tibia (either medial, lateral, anterior, posterior, or rotation) during active knee flexion and extension, depending on which are the limited/painful movements for each patient.~The content and pictures of the neuroscience education (NE) will be based on the text Explicando el dolor (Spanish version of Explain Pain).
Study NCT02246088 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MT + E
Description: Program of education based on the traditional biomedical model (i.e. through visualization of several videos related to anatomy, biomechanics and surgical procedure of the knee), plus the same manual treatment as per the MT+NE group
Study NCT04051216 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education information system
Description: Participants will receive a mobile tablet as an educational intervention
Study NCT04051216 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activity monitor
Description: Participants will receive at least 1 of 4 activity monitoring devices
Study NCT04051216 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Participants will be interviewed about their experience using the device(s)
Study NCT04051216 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Participants will receive surveys
Study NCT04051216 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03449199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMX-049
Description: A certain dose of TMX-049 to be taken orally, once daily
Study NCT03449199 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to be taken orally, once daily
Study NCT00805402 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: flow cytometry
Study NCT00890331 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TeamWork CS Sessions
Description: The intervention focuses on an authoritative parenting approach that emphasizes continued parental involvement in daily disease care. Dyadic coping skills of communication, problem solving, conflict resolution, along with attitude and behavior change are highlighted. Families meet with a study interventionist in conjunction with four consecutive medical appointments.
Study NCT00890331 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Education
Description: Diabetes Education The education comparison group meets with an educational interventionist in conjunction with four consecutive medical appointments. This group focuses on diabetes educational and resource support for parents and their youth with type 1 diabetes.
Study NCT04341272 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Intermittent Pneumatic Compression Device (FDA approved)
Description: Compression Device placed on either upper or lower extremity for DVT prophylaxis following surgery
Study NCT04341272 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent Pneumatic Compression Device (FDA approved)
Description: Compression Device placed on either upper or lower extremity for DVT prophylaxis following surgery
Study NCT03188692 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DPT-IPV-Hib (Combined Vaccine)
Description: 0.5mL, intramuscular injection, 3 times with the 3-8weeks intervals then an additional injection after 6-13 months.
Study NCT04100824 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stellate ganglion block by transcranial doppler
Description: stellate ganglion block is a block of sympathetic ganglion
Study NCT04100824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimodipine
Description: Nimodipine 60mg every 4h
Study NCT04100824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nimodipine
Description: Nimodipine 60mg every 4h
Study NCT00798382 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: soy protein formula
Description: ad lib for 0-35 days of age
Study NCT00798382 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Commercially available soy formula
Description: ad lib for 0-35 days of age
Study NCT00798382 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soy formula experimental #2
Description: ad lib for 0-35 days of age
Study NCT00611884 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Treat-to-target dose titration scheme, s.c. injection.